Clinical Trial Update: Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions [Phase 2]

View source ↗

Summary

An open-label extension Phase 2 trial evaluating the safety and efficacy of TNX-102 SL for military-related PTSD has completed, with results posted on 2025-02-0…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Stress Disorder

Drugs mentioned

• TNX-102 SL (cyclobenzaprine hydrochloride)

Snippet

Sponsor: Tonix Pharmaceuticals, Inc. | Conditions: PTSD | Phase 2 | Status: COMPLETED | Results posted: 2025-02-06